Safety and efficacy of natalizumab in children with multiple sclerosis

Neurology

Volumn 75, Issue 10, 2010, Pages 912-917

  Ghezzi, A ^a   Pozzilli, C ^b   Grimaldi, L M E ^c   Morra, V Brescia ^d   Bortolon, F ^e   Capra, R ^f   Filippi, M ⁱ   Moiola, L ^j   Rocca, M A ⁱ   Rottoli, M ^g   Sarchielli, P ^h   Zaffaroni, M ^a   Comi, G ^a,j  

^a Hospital of Gallarate   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Fondazione Istituto San Raffaele G Giglio   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e Ospedale di Vicenza   (Spain)

^f USD Neurologia Centro di Riferimento Regionale per la Sclerosi Multipla   (Italy)

^g OSPEDALI RIUNITI   (Italy)

^h UNIVERSITY OF PERUGIA   (Italy)

ⁱ Institute of Experimental Neurology   (Italy)

^j SAN RAFFAELE HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GADOLINIUM; GLATIRAMER; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; MONOCLONAL ANTIBODY;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DIARRHEA; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; LEUKOCYTE COUNT; LYMPHOCYTOPENIA; MALE; MULTIPLE SCLEROSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PATIENT ASSESSMENT; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; RELAPSE; SCHOOL CHILD; SIDE EFFECT; TREATMENT DURATION; VERTIGO; BRAIN; CLINICAL TRIAL; HOSPITALIZATION; PATHOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADOLESCENT; ANTIBODIES, MONOCLONAL; BRAIN; CHILD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77957047229     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181f11daf     Document Type: Article

References (29)

1. Ghezzi A, Deplano V, Faroni J, et al. Multiple sclerosis in childhood: clinical features of 149 cases. Mult Scler 1997; 3:43-46.
2. Boiko A, Vorobeychik G, Paty D, et al. Early onset multiple sclerosis: a longitudinal study. Neurology 2002;59: 1006-1010.
3. Simone IL, Carrara D, Tortorella C, et al. Course and prognosis in early-onset MS: comparison with adult-onset forms. Neurology 2002;59:1922-1928.
4. Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007;365:2603-2613.
5. Banwell B, Ghezzi A, Bar-Or A, et al. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurol 2007;6:887-902.
6. Ghezzi A, Pozzilli C, Liguori M, et al. Prospective study of multiple sclerosis with early onset. Mult Scler 2002;8:115-118.
7. Gusev E, Boiko A, Bikova O, et al. The natural history of early onset multiple sclerosis: comparison of data from Moscow and Vancouver. Clin Neurol Neurosurg 2002; 104:203-207.
8. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009;66:54-59.
9. Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002;58:169-178.
10. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of Natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354: 899-910.
11. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354:924-933.
12. Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007;6:431-441.
13. Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale. Neurology 1983;33:1444-1452.
14. Miller DH, Barkkhof F, Berry I, et al. Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991;54:683-688.
15. Filippi M, Gawne-Cain ML, Gasperini C, et al. Effect of training and different measurement strategies on the repro-ducibility of brain MRI lesion load measurements in multiple sclerosis. Neurology 1998;50:238-244.
16. Makhani N, Gorman MP, Branson HM, et al. Cyclophos-phamide therapy in pediatric multiple sclerosis. Neurology 2009;72:2076-2082.
17. Boriello G, Prosperini L, Lucchetti A, Pozzilli C. Natali-zumab treatment in pediatric multiple sclerosis: a case report. Eur J Paediatr Neurol 2009;13:67-71.
18. Appleton RE, Boggild M. Natalizumab in paediatric multiple sclerosis and service implication. Dev Med Child Neurol 2009;51:758-759.
19. Huppke P, Stark W, Zurcher C, et al. Natalizumab in paediatric multiple sclerosis and service implication. Arch Neurol 2008;65:1655-1658.
20. Chabas D, Castello-Trivino T, Mowry EM, et al. Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype. Neurology 2008;71:1090-1093.
21. Waubant E, Chabas D, Okuda D, et al. Difference in disease burden and activity in pediatric patients on brain magnetic resonance imaging at time of multiple sclerosis onset vs adults. Arch Neurol 2009;66:967-971.
22. Rocca MA, Absinta M, Ghezzi A, et al. Is a preserved functional reserve a mechanism limiting clinical impairment in pediatric MS patients? Hum Brain Mapp 2009;30:2844-2851.
23. Tortorella P, Rocca MA, Mezzapesa DM, et al. MRI quantification of gray and white matter damage in patients with early-onset multiple sclerosis. J Neurol 2006;253:903-907.
24. Mesaros S, Rocca MA, Absinta M, et al. Evidence of tha-lamic gray matter loss in pediatric multiple sclerosis. Neurology 2008;70:1107-1112.
25. Hutchinson M, Kappos L, Calabresi PA, et al, for the AFFIRM and SENTINEL Investigators. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analysis of AFFIRM and SENTINEL. J Neurol Epub 2009 Mar 18.
26. Hyams JS, Wilson DC, Thomas A, et al. Natalizumab therapy for moderate to severe Crohn disease in adolescents. J Pediatr Gastroenterol Nutr 2007;44:185-191.
27. Clifford BD, DeLuca A, Simpson DM, et al. Natalizumab-associated progressive multifocal leukoen-cephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010;9:438-446.
28. Tedeschi G, Amato MP, D'Alessandro R, et al. The pharmacovigilance program on natalizumab in Italy: 2 years of experience. Neurol Sci 2009;30(suppl 2):S163-S165.
29. Sweet TM, Del Valle L, Khalili K. Molecular biology and immunoregulation of human neurotropic JC virus in CNS. J Cell Physiol 2002;191:249-256.